+7 (777) 001 44 99
Қазақша
Русский
English
Қазақша
Русский
English
ПОДЕЛИТЬСЯ
Kazakhstan and U.S. scientists are planning to jointly study aging processes and methods of their retardation, Tengrinews.kz reports. Employees of Asfendiyarov Kazakhstan National Medical University met with a delegation from the Buck Institute for Research on Aging, California. CEO of the American Institute Brian K. Kennedy, Ph.D., said his organization had been studying aging for many years. He said that Buck was working on several directions: studying use of gene engineering and biotechnologies and researching the main types of chronic diseases that manifest themselves especially sharply in elderly age. Kennedy stressed that the Institute decided to organize a global campaign to study aging. He said that the organization was looking for partners for experience exchange and that Kazakhstan National Medical University had been performing its own researches in this area and could become one of the partners. Kennedy noted that Buck Institute was ready to accept Kazakhstan experts for trainings. Kazakhstan party is also ready to share the results of its own scientific researches. President of the Kazakhstan University Aikan Akanov told that his American colleagues could be interested in the experimental researches made by the University's scientists. The Kazakhstan experts studied the situation in five oblasts of Kazakhstan. According to Akanov, over 8 percent of Kazakhstan population are over 65 y.o. This is a high index that shows Kazakhstan as a fast-aging nation. That's why this kind of research is very important for the country. Kazakhstan and U.S. scientists are going to discuss a new scientific discovery of the Buck Institute. The American experts discovered that rapamycin, the substance produced by soil bacteria, retards the aging process significantly. Even if a person start taking it in an elderly age, it is able to prolong the life expectancy by 12-15 percent. However, rapamycin is no remedy against early aging, because the substance has critical side effects: it suppresses the immunity and increases the risk of developing diabetes. The Americans are intent to solve the issue by retaining rapamycin's anti-aging properties and eliminating its negative side effects jointly with scientists from different countries, including Kazakhstan. By Dmitriy Khegai
Kazakhstan and U.S. scientists are planning to jointly study aging processes and methods of their retardation, Tengrinews.kz reports. Employees of Asfendiyarov Kazakhstan National Medical University met with a delegation from the Buck Institute for Research on Aging, California.
CEO of the American Institute Brian K. Kennedy, Ph.D., said his organization had been studying aging for many years. He said that Buck was working on several directions: studying use of gene engineering and biotechnologies and researching the main types of chronic diseases that manifest themselves especially sharply in elderly age.
Kennedy stressed that the Institute decided to organize a global campaign to study aging. He said that the organization was looking for partners for experience exchange and that Kazakhstan National Medical University had been performing its own researches in this area and could become one of the partners. Kennedy noted that Buck Institute was ready to accept Kazakhstan experts for trainings.
Kazakhstan party is also ready to share the results of its own scientific researches. President of the Kazakhstan University Aikan Akanov told that his American colleagues could be interested in the experimental researches made by the University's scientists. The Kazakhstan experts studied the situation in five oblasts of Kazakhstan.
According to Akanov, over 8 percent of Kazakhstan population are over 65 y.o. This is a high index that shows Kazakhstan as a fast-aging nation. That's why this kind of research is very important for the country.
Kazakhstan and U.S. scientists are going to discuss a new scientific discovery of the Buck Institute. The American experts discovered that rapamycin, the substance produced by soil bacteria, retards the aging process significantly. Even if a person start taking it in an elderly age, it is able to prolong the life expectancy by 12-15 percent. However, rapamycin is no remedy against early aging, because the substance has critical side effects: it suppresses the immunity and increases the risk of developing diabetes. The Americans are intent to solve the issue by retaining rapamycin's anti-aging properties and eliminating its negative side effects jointly with scientists from different countries, including Kazakhstan.
By Dmitriy Khegai
